Recently news suggests low vitamin D levels have been associated with increased risk of COVID-related morbidity and mortality. We know that vitamin D is a safe fat soluable vitamin that is difficult to "overdose" on.  What should the pharmacist know in terms of repletion dose and signs of toxicity? Since many patients do not get enough vitamin D in their diets, large medical societies and organizations recommend daily vitamin D for this reason.   This episode will focus not on the claims of efficacy of Vitamin D in COVID, but will instead discuss how your patients can replete vitamin D levels and the risks of toxicity in overrepletion.This episode is accredited for CPE.  For CE details and to claim credit click here: https://bit.ly/2N87PCD See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID,  is the subject of this episode.This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Buprenorphine has been shown in numerous studies to be safe and effective in opioid use disorder, yet < 10% patients with Opioid Use Disorder receive drug treatment. In this episode, we discuss what the general pharmacist needs to know about the most powerful weapon we have for Opioid Use Disorder: buprenorphineThis episode is accredited for CPE.  This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3dPEj0i See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Geoff Wall, PharmD & Jamie Pitlick, PharmD discussing SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar.  Recently SGLTs, which are currently indicated for Type 2 diabetes, have been investigated and received FDA approval for Heart failure with reduced ejection fraction (HFrEF).  Listen in to this episode to discover more about how these drugs work in this (HFrEF) disease state.This episode is accredited for CPE.  This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/2ApMvWw See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

GameChangers: In this episode, we describe the latest information concerning hypercoagulability with COVID-19 infection.  In this episode, we describe the latest information concerning hypercoagulability with COVID-19 infection.  Emerging evidence suggests that patients with COVID infection may be hypercoagulable and prone to clotting. Listen in as we discuss the evidence surrounding this issue and how to address therapeutic issues in anticoagulation in this population.This episode is accredited for CPE.  This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3he73SF See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram